1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,900 | 8,990 | 24.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 75 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 152 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 213 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 125 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 647 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
| 30.10.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2024 | 120 | GlobeNewswire (Europe) | "It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that... ► Artikel lesen | |
| 23.07.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2024 | 144 | GlobeNewswire (Europe) | "Devyser continued to report high sales growth in the second quarter. Organic growth compared with the same quarter of last year amounted to 41 percent in SEK. We won several large tenders during the... ► Artikel lesen | |
| 08.05.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2024 | 140 | GlobeNewswire (Europe) | "Devyser reports continued strong sales growth and high gross margins for the quarter. It is particularly pleasing to see that our investment in the Americas is continuing to produce results, with growth... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 74,06 | +0,23 % | Medtronic Submits 510(k) Application To FDA For Interoperable Insulin Pump | WASHINGTON (dpa-AFX) - Medtronic plc (MDT), Thursday announced it has submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) seeking clearance for an interoperable pump.... ► Artikel lesen | |
| HCA HEALTHCARE | 298,60 | +0,74 % | AbbVie, Colgate-Palmolive, HCA Holdings lead Friday's earnings parade | ||
| LANTHEUS | 90,02 | +0,81 % | Lantheus Holdings, Inc.: Lantheus Completes Acquisition of Evergreen Theragnostics | BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
| AMEDISYS | 80,50 | 0,00 % | Amedisys Q1 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Amedisys (AMED) announced earnings for its first quarter that increased from the same period last year and beat the Street estimates.The company's bottom line totaled... ► Artikel lesen | |
| ENVISTA | 14,100 | +1,44 % | Bausch + Lomb To Return EnVista Intraocular Lenses To Market Following Recall; Stock Up | ||
| CAREDX | 16,850 | +7,09 % | CareDx, Inc.: CareDx gibt Studie bekannt, die zeigt, dass AlloSeq cfDNA bei der Erkennung von Abstoßungsreaktionen bei Organtransplantationspatienten äußerst genau ist | AlloSeq cfDNA entspricht der Leistung des bewährten AlloSure-Tests CareDx bringt mit AlloSeq cfDNA ein innovatives nicht-invasives Transplantationsmonitoring für Patienten auf internationaler... ► Artikel lesen | |
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal Second Quarter 2025 Results | Reports 23 Percent Increase in ARR to $19.1 Million and 61 Net New Platform Deployments HENDERSON, Nev., Feb. 13, 2025 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), the leading... ► Artikel lesen | |
| GT BIOPHARMA | 2,330 | 0,00 % | GT Biopharma, Inc. - 10-K/A, Annual Report | ||
| CARMAT | 0,875 | +0,57 % | CARMAT Receives FDA Conditional Approval to Initiate the Second Cohort of the EFS Study in the United States | Recruitment of the second cohort expected to begin in H2 2025
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming... ► Artikel lesen | |
| CHEMOMETEC | 63,65 | -1,55 % | Chemometec A/S: Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings | ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue... ► Artikel lesen | |
| HAMILTON THORNE | 1,490 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 02.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.12.2024ISIN NameCA81012R1064 SCOTTIE... ► Artikel lesen | |
| ARRAIL GROUP | 0,180 | -2,17 % | ARRAIL GROUP (06639): NEXT DAY DISCLOSURE RETURNS | ||
| POLAREAN IMAGING | 0,008 | +1.400 % | Polarean Imaging PLC - Expansion of Xenon MRI imaging platform | ||
| PROMIMIC | 2,140 | -0,47 % | Karolinska Development AB (publ): Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface | STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacterial... ► Artikel lesen | |
| FRESENIUS | 39,850 | +0,94 % | BARCLAYS stuft Fresenius SE auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Fresenius von 44,00 auf 43,50 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. Die Bad Homburger dürften... ► Artikel lesen |
DEVYSER DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +3,19 % bei einem Aktienkurs von 9,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.
